The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study
- PMID: 25660258
- PMCID: PMC4393776
- DOI: 10.1007/s00125-015-3514-y
The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study
Abstract
Aims/hypothesis: Islet autoantibodies, in addition to elevated blood glucose, define type 1 diabetes. These autoantibodies are detectable for a variable period of time before diabetes onset. Thus, the occurrence of islet autoantibodies is associated with the beginning of the disease process. The age at, and order in, which autoantibodies appear may be associated with different genetic backgrounds or environmental exposures, or both.
Methods: Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8 and DR3/3) were enrolled and prospectively followed with standardised autoantibody assessments quarterly throughout the first 4 years of life and then semi-annually thereafter.
Results: Autoantibodies appeared in 549/8,503 (6.5%) children during 34,091 person-years of follow-up. Autoantibodies at 3 (0.1%) and 6 (0.2%) months of age were rare. Of the 549, 43.7% had islet autoantibodies to insulin (IAA) only, 37.7% had glutamic acid decarboxylase autoantibodies (GADA) only, 13.8% had both GADA and IAA only, 1.6% had insulinoma antigen-2 only and 3.1% had other combinations. The incidence of IAA only peaked within the first year of life and declined over the following 5 years, but GADA only increased until the second year and remained relatively constant. GADA only were more common than IAA only in HLA-DR3/3 children but less common in HLA-DR4/8 children.
Conclusions/interpretation: Islet autoantibodies can occur very early in life and the order of appearance was related to HLA-DR-DQ genotype.
Conflict of interest statement
The authors declare that there is no duality of interest associated with this manuscript.
Figures



References
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK95300/DK/NIDDK NIH HHS/United States
- U01 DK63861/DK/NIDDK NIH HHS/United States
- UC4 DK63863/DK/NIDDK NIH HHS/United States
- U01 DK63821/DK/NIDDK NIH HHS/United States
- UC4 DK063821/DK/NIDDK NIH HHS/United States
- UC4 DK063836/DK/NIDDK NIH HHS/United States
- HHSN267200700014C/DK/NIDDK NIH HHS/United States
- UC4 DK63865/DK/NIDDK NIH HHS/United States
- U01 DK063861/DK/NIDDK NIH HHS/United States
- UL1 TR001427/TR/NCATS NIH HHS/United States
- U01 DK063790/DK/NIDDK NIH HHS/United States
- UC4 DK100238/DK/NIDDK NIH HHS/United States
- U01 DK63829/DK/NIDDK NIH HHS/United States
- UL1 TR001082/TR/NCATS NIH HHS/United States
- UC4 DK63829/DK/NIDDK NIH HHS/United States
- U01 DK63836/DK/NIDDK NIH HHS/United States
- UC4 DK63821/DK/NIDDK NIH HHS/United States
- UC4 DK063863/DK/NIDDK NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- UC4 DK63836/DK/NIDDK NIH HHS/United States
- U01 DK063836/DK/NIDDK NIH HHS/United States
- U01 DK063829/DK/NIDDK NIH HHS/United States
- U01 DK063865/DK/NIDDK NIH HHS/United States
- UC4 DK095300/DK/NIDDK NIH HHS/United States
- UC4 DK063861/DK/NIDDK NIH HHS/United States
- U01 DK63865/DK/NIDDK NIH HHS/United States
- UC4 DK063829/DK/NIDDK NIH HHS/United States
- U01 DK063863/DK/NIDDK NIH HHS/United States
- U01 DK63790/DK/NIDDK NIH HHS/United States
- UC4 DK063865/DK/NIDDK NIH HHS/United States
- U01 DK63863/DK/NIDDK NIH HHS/United States
- UC4 DK63861/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials